Compare · FRES vs ILMN
FRES vs ILMN
Side-by-side comparison of Fresh2 Group Limited (FRES) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRES and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN carries a market cap of $31.68B.
- ILMN has hit the wire 15 times in the past 4 weeks while FRES has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for FRES).
- Company
- Fresh2 Group Limited
- Illumina Inc.
- Price
- -
- -
- Market cap
- -
- $31.68B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2000
- News (4w)
- 0
- 15
- Recent ratings
- 0
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest FRES
- SEC Form 6-K filed by Fresh2 Group Limited
- SEC Form 6-K filed by Fresh2 Group Limited
- Fresh2 Group Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing
- Fresh2 Group Ltd. Announces Receipt of an Additional Delinquency Compliance Alert Notice from Nasdaq
- SEC Form 6-K filed by Fresh2 Group Limited
- Fresh2 Has Partnered With Over 50 Influencers, Leveraging Key Partnerships To Fresh2's Video E-Commerce Business Is Rapidly Expanding Its Market Presence In The E-Commerce Sector
- Fresh2 Announces Collaboration with Over 50 Influencers in Video E-commerce
- Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
- Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
- Fresh2 Group Limited Announces 1-For-10 Reverse ADS Split, Expected To Become Effective On July 10, 2024
Latest ILMN
- Director Meister Keith A. sold $61,093,041 worth of shares (280,091 units at $218.12) (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $58,142 worth of shares (267 units at $217.76), decreasing direct ownership by 2% to 14,029 units (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.88% to 40,567 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D covered exercise/tax liability with 150 shares, decreasing direct ownership by 1% to 14,296 units (SEC Form 4)
- SVP, Chief People Officer Leckman Patricia covered exercise/tax liability with 208 shares, decreasing direct ownership by 0.98% to 21,120 units (SEC Form 4)
- Chief of Global Operations Pegels Kevin Carl covered exercise/tax liability with 604 shares, decreasing direct ownership by 2% to 28,434 units (SEC Form 4)
- Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
- Director Meister Keith A. sold $66,560,212 worth of shares (281,433 units at $236.50) (SEC Form 4)
- Illumina selected to help bring precision medicine into everyday healthcare in Singapore
- SEC Form 10-Q filed by Illumina Inc.